Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasome-based nonmyelosuppressive induction therapy

Bone Marrow Transplantation

Volumn 33, Issue 6, 2004, Pages 623-628

  Anagnostopoulos, A ^a   Aleman, A ^a   Yang, Y ^a   Donato, M ^a   Weber, D ^a   Champlin, R ^a   Smith, T ^a   Alexanian, R ^a   Giralt, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous stem cell transplant; Dexamethasone; Multiple myeloma; Nonmyelosuppressive induction

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HOLMIUM; MELPHALAN; THIOTEPA; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CONTROLLED STUDY; DATA ANALYSIS; DRUG EXPOSURE; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

DEXAMETHASONE; HUMANS; IMMUNOSUPPRESSION; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 1842535080     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704398     Document Type: Article

References (19)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Hahn T, Wingard J, Anderson K et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence based review. Biol Blood Marrow Transpl 2003; 9: 4-37.
3. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32: 20-30.
4. Kyle RA. Multiple myeloma. Diagnostic challenges and standard therapy. Semin Hematol 2001; 38: 11-14.
5. Goldman JM, Szydlo R, Horowitz MM et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235-2238.
6. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
7. McIntyre OR, Pajak TF, Kyle RA et al. Response rate and survival in myeloma patients receiving prednisone alone. Med Pediat Oncol 1985; 13: 239-243.
8. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
9. Weber DM, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
10. Rajkumar VS, Hayman SR, Gerts MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
11. Dimopoulos MA, Weber D, Kantarjian H et al. Hyper-CVAD for VAD resistant multiple myeloma. Am J Hematol 1996; 52: 77-81.
12. Rawstron AC, Owen RG, Davies FE et al. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol 1997; 97: 46-55.
13. Giralt S, Alexanian R, Podoloff D et al. Results of a phase I/II trial with 166Ho-Dotmp plus high dose chemotherapy in patients with multiple myeloma. In: VIIIth International Myeloma Workshop, 2001. Banff, Alberta, Canada.
14. Shimoni A, Smith TL, Aleman A et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: An intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821-828.
15. Donato M, Weber D, Alexanian R et al. High dose topotecan melphalan and cyclophosphamide (TMC): A new regimen for autologous transplantation in multiple myeloma. In: ASH, 2000. San Francisco, California..
16. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
17. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Crowley J, Jacobson J, Alexanian R. Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. Semin Hematol 2001; 38: 203-208.
19. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 1858-1868.